Our findings suggest that STMN1 could serve as a clinical indicator of poor response to taxane-based treatments, and that targeting STMN1 may help overcome taxane resistance, potentially improving treatment outcomes in advanced PCa. Here, STMN1 is linked to posterior cortical atrophy.